In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 226 to 250 of 303

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)	Technology appraisal guidance	TBC
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]	Technology appraisal guidance	18 June 2025
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]	Technology appraisal guidance	TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]	Technology appraisal guidance	TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]	Technology appraisal guidance	TBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]	Technology appraisal guidance	TBC
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]	Technology appraisal guidance	TBC
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]	Technology appraisal guidance	29 January 2025
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]	Technology appraisal guidance	TBC
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]	Technology appraisal guidance	TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284	Technology appraisal guidance	TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]	Technology appraisal guidance	TBC
Seladelpar for previously treated primary biliary cholangitis ID6429	Technology appraisal guidance	10 September 2025
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]	Technology appraisal guidance	TBC
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]	Technology appraisal guidance	TBC
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]	Technology appraisal guidance	TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]	Technology appraisal guidance	TBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441	Technology appraisal guidance	TBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346	Technology appraisal guidance	TBC
Sipavibart for preventing COVID 19 [ID6282]	Technology appraisal guidance	TBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]	Technology appraisal guidance	12 November 2025

Results per page

10
25
50
All